1. Home
  2. AKBA vs HTBK Comparison

AKBA vs HTBK Comparison

Compare AKBA & HTBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.60

Market Cap

729.1M

Sector

Health Care

ML Signal

HOLD

HTBK

Heritage Commerce Corp

HOLD

Current Price

$12.08

Market Cap

667.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKBA
HTBK
Founded
2007
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
729.1M
667.4M
IPO Year
2014
1998

Fundamental Metrics

Financial Performance
Metric
AKBA
HTBK
Price
$1.60
$12.08
Analyst Decision
Strong Buy
Buy
Analyst Count
6
5
Target Price
$6.25
$12.70
AVG Volume (30 Days)
2.9M
1.2M
Earning Date
11-10-2025
01-22-2026
Dividend Yield
N/A
4.33%
EPS Growth
N/A
N/A
EPS
N/A
0.70
Revenue
$225,071,000.00
$187,676,000.00
Revenue This Year
$52.38
$13.16
Revenue Next Year
$22.45
$7.61
P/E Ratio
N/A
$17.16
Revenue Growth
32.49
10.94
52 Week Low
$1.45
$8.09
52 Week High
$4.08
$12.89

Technical Indicators

Market Signals
Indicator
AKBA
HTBK
Relative Strength Index (RSI) 41.83 58.32
Support Level $1.58 $11.06
Resistance Level $1.71 $12.89
Average True Range (ATR) 0.07 0.25
MACD 0.02 -0.06
Stochastic Oscillator 16.67 20.39

Price Performance

Historical Comparison
AKBA
HTBK

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About HTBK Heritage Commerce Corp

Heritage Commerce Corp operates as a bank holding company. The company, through its subsidiary, offers commercial banking services to small and medium-sized businesses and their owners, managers, and employees. It operates through two reportable segments, namely Banking and Factoring. A majority of its revenue is generated from the Banking segment, which provides various loan products, including commercial and industrial loans, commercial real estate loans, construction loans, etc. This segment also focuses on deposit generation on relationship accounts, encompassing non-interest bearing demand, interest bearing demand, money market accounts, certificates of deposit, and savings accounts.

Share on Social Networks: